APAC Breast Cancer Therapeutics Market Report 2022 to 2030

APAC Breast Cancer Therapeutics Market Analysis

$ 3999

The APAC breast cancer therapeutics market is expected to grow from $3.82 Bn in 2022 to $11.03 Bn in 2030 with a CAGR of 14.17% for the year 2022-2030 as a result of rising breast cancer prevalence and supportive government policies in the APAC region. The market is segmented by therapy, by cancer type, and by distribution channel. Some of the leading companies in the APAC breast cancer therapeutics market are AbbVie, AstraZeneca, and Eisai.

ID: IN10APPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Asia - Pacific AUTHOR: Parul Choudhary

Buy Now

APAC Breast Cancer Therapeutics Market Executive Analysis

The APAC breast cancer therapeutics market size is at around $3.82 Bn in 2022 and is projected to reach $11.03 Bn in 2030, exhibiting a CAGR of 14.17% during the forecast period. Asia's total healthcare spending is anticipated to increase to $2.27 Tn by 2026 from $1.69 Tn in 2017, driven by greater healthcare costs, an increase in the prevalence of chronic diseases, a growing middle class, and a general shift in the aging population. On the strength of strong regional demand and favorable demographics, the APAC healthcare market is on track to experience exceptional growth. Oncology is where most medication development in Asia is concentrated. Because lung, stomach, breast, and colorectal cancers are more common in Asia than in the West.

Incidence and mortality rates for breast cancer have consistently climbed across the APAC area over the past 20 years, with levels in countries like Japan, Korea, and Australia nearing those in the USA and the EU. As the world's population continues to grow, especially in China and India, the socioeconomic burden of breast cancer is anticipated to rise during the coming ten years. Regardless of geography, early menarche, late menopause, older age at the first full-term pregnancy, and no breastfeeding are some of the risk factors for breast cancer in Asian cultures. Breast lumps, skin irritation, skin that is red or peeling around the breasts, pain in any breast location, etc. are all signs of breast cancer. The drugs work by shrinking tumors, slowing the spread of cancer, and increasing the likelihood that the disease will be cured. Among the treatments for breast cancer include hormone therapy, chemotherapy, and targeted therapy.

APAC breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

It is projected that the APAC region's rising breast cancer prevalence will favorably affect the APAC breast cancer therapeutics market. Supportive actions taken by public agencies and local governments are anticipated to raise public knowledge of breast cancer and motivate patients to receive the best possible care. Moreover, the APAC breast cancer therapeutics market is growing as a result of recent product approvals, launches, and breakthroughs in breast cancer treatment.

Market Restraints

Limited screening options for the diagnosis of breast cancer, long-term therapies that degrade health, and unavailability of healthcare across diverse locations are responsible for restraining the APAC breast cancer therapeutics market expansion. Furthermore, the market expansion is hampered by the adverse effects caused by breast cancer therapeutics as well as their high cost.

Competitive Landscape

Key Players

AbbVie
AstraZeneca
Eisai
GlaxoSmithKline
Merck
Pfizer
Sanofi
Sun Pharmaceutical Industries
Takeda Pharmaceutical

Healthcare Policies and Regulatory Landscape

The APAC area has a wide range of health coverage laws for breast cancer treatment based on the nation and particular insurance plan. However, generally speaking, most governments in the area offer their citizens some sort of public health insurance, which may pay all or part of the expense of breast cancer treatment. There may also be private insurance choices, which can offer more possibilities for coverage. Patients may occasionally need to pay for treatment upfront before submitting a claim for reimbursement with their insurance company. Furthermore, certain nations might have regulations or programs in place to offer patients who are having trouble affording cancer treatment additional financial support. Patients are urged to look into and use any financial aid programs that are offered.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.